Payment overview · 2025
General Payments
$424.09
20 reported records · 9 companies
Healthcare provider profile · identity verified
Keith R. Baker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HILLSDALE, MI · NPI 1538271267
Verified facts
What the public records show
CMS Open Payments records show Keith R. Baker, M.D. received $424.09 in general payments during 2025 across 20 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $91.88 | 21.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.39 | 19.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.05 | 15.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.52 | 12.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.22 | 11.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.02 | 6.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.42 | 6.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.89 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.70 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.09 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $91.88 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.39 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.52 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.52 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 125 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 48 |
| Lisinopril | Lisinopril | 162 | 52 |
| Omeprazole | Omeprazole | 161 | 53 |
| Farxiga | Dapagliflozin Propanediol | 147 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 133 | 33 |
| Losartan Potassium | Losartan Potassium | 131 | 46 |
| Montelukast Sodium | Montelukast Sodium | 125 | 41 |
| Famotidine | Famotidine | 119 | 31 |
| Jardiance | Empagliflozin | 112 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 33 |
| Felodipine Er | Felodipine | 97 | 27 |
| Metformin Hcl | Metformin Hcl | 96 | 31 |
| Trazodone Hcl | Trazodone Hcl | 95 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 87 | 38 |
| Eliquis | Apixaban | 87 | 21 |
| Azithromycin | Azithromycin | 86 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 31 |
| Gabapentin | Gabapentin | 86 | 25 |
| Allopurinol | Allopurinol | 84 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 32 |
| Tramadol Hcl | Tramadol Hcl | 77 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 29 |
| Spironolactone | Spironolactone | 75 | 23 |
| Buspirone Hcl | Buspirone Hcl | 73 | 19 |
| Ramipril | Ramipril | 73 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 23 |
| Prednisone | Prednisone | 69 | 49 |
| Valsartan | Valsartan | 69 | 19 |
| Finasteride | Finasteride | 63 | 18 |
| Potassium Chloride | Potassium Chloride | 60 | 24 |
| Meloxicam | Meloxicam | 58 | 26 |
| Dexamethasone | Dexamethasone | 56 | 40 |
| Ezetimibe | Ezetimibe | 56 | 19 |
| Atenolol | Atenolol | 55 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 14 |
| Telmisartan | Telmisartan | 54 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 17 |
| Torsemide | Torsemide | 52 | 19 |
| Glimepiride | Glimepiride | 49 | 13 |
| Alprazolam | Alprazolam | 48 | 16 |
| Furosemide | Furosemide | 47 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Baclofen | Baclofen | 42 | 12 |
| Celecoxib | Celecoxib | 42 | 18 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | 15 |
| Fluconazole | Fluconazole | 33 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Carvedilol | Carvedilol | 30 | 12 |
| Diflunisal | Diflunisal | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Sulindac | Sulindac | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Indapamide | Indapamide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Simvastatin | Simvastatin | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.09 · 20 records | Otsuka America Pharmaceutical, Inc. | CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, Korlym, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Wegovy, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error